Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of lymphoma by blocking blood flow to the cancer. Giving fludarabine and cyclophosphamide together with thalidomide may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with thalidomide works in treating patients with angioimmunoblastic T-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Cyclophosphamide; Fludarabine; Fludarabine phosphate; Thalidomide; Vidarabine

Criteria

DISEASE CHARACTERISTICS:

• Newly diagnosed angioimmunoblastic T-cell lymphoma

• Measurable disease (i.e., anatomically assessable)

PATIENT CHARACTERISTICS:

• WHO/ECOG performance status 0-2

• Serum creatinine ≤ 2.5 times upper limit of normal (ULN)

• Bilirubin ≤ 2.5 times ULN

• Alkaline phosphatase ≤ 2.5 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception before, during, and after study treatment

• No known seropositivity for hepatitis B virus, hepatitis C virus, or HIV

• No active second malignancy or other concomitant serious medical condition, in particular peripheral neuropathy

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy for angioimmunoblastic T-cell lymphoma